Quantitative Digital Pathology Technique as a Tool for Cancer Progression

PCa is the second and third leading cause of cancer death for American and Canadian men, respectively. Prostate-Specific Antigen (PSA) screening is an effective method to diagnose PCa at early stages, however, over-diagnosis/treatment following PSA is detrimental to life quality. Although Active Surveillance (AS) is a very appealing approach for men with early stage PCa, more than 30% of AS patients will progress and require treatment. Moreover, Current diagnostic methods do not provide a sufficiently accurate and reliable means for stratifying risk because they cannot delineate the aggressive, potential lethal from the indolent, slow growing PCa cases. Our goal is to develop simple, objective, automated, widely available and cost-effective QDP tools that will provide reliable prognostic information for differentiating indolent from aggressive prostate cancers. Success with this work will improve life quality of patients significantly and decrease medical costs.

Faculty Supervisor:

Pierre Lane;Haishan Zeng

Student:

Partner:

Logipath Medical Inc;BC Cancer Foundation

Discipline:

Engineering

Sector:

Professional, scientific and technical services

University:

The University of British Columbia

Program: